Group 1 - The core point of the news is that Maiwei Biotech's stock price has dropped by 5.29%, currently trading at 42.29 CNY per share, with a total market capitalization of 16.899 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, focuses on the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 128 million CNY, with a turnover rate of 1.46% [1] Group 2 - Huafu Fund has a significant holding in Maiwei Biotech, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 170,000 shares, accounting for 6.49% of the fund's net value [2] - The fund has experienced a floating loss of approximately 401,200 CNY today, despite having a year-to-date return of 43.71% [2] - The fund manager, Liao Qingyang, has been in position for nearly 4 years, with the fund's total asset size currently at 74.027 million CNY [2]

Group 1 - Insurance capital is accelerating its layout in the equity market under policy guidance, with a total of over 4700 company visits since the second half of 2025 [1][2] - Leading asset management and pension insurance companies are the main players in this trend, with Taikang Asset Management conducting over 280 visits, followed by Dajia Asset Management and Huatai Asset Management [1][2] - The technology and pharmaceutical sectors are the primary focus areas, with companies like Maiwei Biotech and Borui Pharmaceutical receiving multiple visits [1][4] Group 2 - The research activity is widespread across various A-share sectors, with over 70% of visits concentrated in Shenzhen Main Board, ChiNext, and STAR Market [2] - Some stocks have shown strong market performance post-insurance visits, with companies like Zhongji Xuchuang and Taotao Automotive doubling their stock prices [2] - Pension insurance companies are also actively participating, with Ping An Pension leading with 171 visits, focusing on both large-cap and small-cap companies [3][4] Group 3 - The dual focus on technology and pharmaceuticals reflects a strategic adjustment in asset allocation due to the low interest rate environment, aiming to build a balanced investment portfolio [3][5] - The pharmaceutical sector, particularly innovative drugs, is attractive for insurance funds due to its long-term investment nature, aligning with the stable characteristics of insurance capital [5] - The hard technology sector is experiencing multiple breakthroughs, with companies like Jing Sheng Machinery and Huichuan Technology being frequently visited [5][6] Group 4 - Traditional sectors, particularly bank stocks, remain a key focus for insurance capital, with a clear "growth in technology + high dividend" strategy [6] - Regional banks are gaining attention, with Jiangsu Bank receiving 17 visits, indicating a shift from the previous preference for state-owned banks [6]

迈威（上海）生物科技股份有限公司 证券代码：688062 证券简称：迈威生物 公告编号：2025-062 迈威（上海）生物科技股份有限公司 关于召开 2025 年半年度暨第三季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 迈威（上海）生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》 及《2025 年半年度报告摘要》，并拟于 2025 年 10 月 31 日披露《2025 年第三季 度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 董事长、总经理：刘大涛先生 董事、副总经理、董事会秘书：胡会国先生 副总经理、财务负责人：华俊先生 投资者关系副总监：郑川川先生 （如遇特殊情况，参会人员可能进行调整。） 四、投资者参加方式 投 资 者 可 于 2025 年 10 月 31 日 （ 星 期 五 ） 10:00-11:00 通 过 网 址 http ...

Core Viewpoint - Maiwei Biotech's stock has shown significant volatility and performance, with a notable increase in share price year-to-date, despite recent declines in revenue and profit margins [1][2]. Group 1: Stock Performance - As of October 21, Maiwei Biotech's stock price increased by 2.02%, reaching 45.55 CNY per share, with a trading volume of 239 million CNY and a turnover rate of 2.62%, resulting in a total market capitalization of 18.202 billion CNY [1]. - The stock has appreciated by 125.50% year-to-date, with a 2.54% increase over the last five trading days, a 7.94% decrease over the last 20 days, and a 26.88% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, Maiwei Biotech reported a revenue of 101 million CNY, reflecting a year-on-year decrease of 12.43%, while the net profit attributable to shareholders was -551 million CNY, a decline of 23.90% compared to the previous period [2]. - As of June 30, 2025, the number of shareholders increased to 17,900, marking an 11.66% rise, while the average number of circulating shares per person decreased by 10.44% to 11,379 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the third-largest shareholder with 4.7426 million shares, marking a new entry [2]. - Xingshan He Run Mixed A (163406) ranked as the fifth-largest shareholder with 3.39 million shares, also a new entry, while Penghua Medical Technology Stock A (001230) was the sixth-largest with 3.1056 million shares, showing a decrease of 1.173 million shares from the previous period [2]. - Several funds, including HSBC Jintrust Smart Manufacturing Pioneer Stock A (001643) and HSBC Jintrust Research Selected Mixed (014423), have exited the top ten circulating shareholders list [2].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].

Core Insights - The 2025 European Society for Medical Oncology (ESMO) conference will take place in Berlin from October 17 to 21, with several domestic companies planning to disclose data [1] - Zai Lab (688266) will present clinical research data for its new drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) at ESMO [1] - ZG006 is the world's first tri-specific antibody targeting DLL3, showing potential as a best-in-class molecule with significant and durable anti-tumor efficacy in SCLC or NEC patients who have failed existing standard treatments [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, expected to treat various solid tumors, and is among the first of its kind to enter clinical research globally [1] Company Developments - Zai Lab reported that ZG005 combined with chemotherapy shows good safety and efficacy in patients with advanced neuroendocrine carcinoma, supporting further clinical research [2] - Aosaikang (002755) announced the presentation of data for its new cMET inhibitor ASKC202 combined with Lapatinib for locally advanced or metastatic non-small cell lung cancer, demonstrating good safety and high tumor response rates [2] - Aosaikang's Lapatinib is its third-generation EGFR TKI, and the company believes that the synergy of its two innovative drug projects will enhance its oncology product pipeline [2] Other Company Announcements - Maiwei Biotech (688062) plans to report data on its B7-H3 targeted antibody-drug conjugate 7MW3711 for advanced solid tumors at ESMO [3] - Kelun Pharmaceutical (002422) will present a study comparing the efficacy and safety of Trastuzumab deruxtecan versus Emicizumab in HER2-positive patients who have previously received Trastuzumab and taxane treatments [3] - Academic conferences are crucial catalysts for innovative drug sectors, with major events like ASCO, ESMO, and WCLC being the most significant in the oncology field [3]

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [8]. Core Insights - The report highlights several catalysts for the sector, including academic conferences, business development (BD) achievements, medical insurance negotiations, and innovative drug directories from commercial insurance [21]. - Key companies to watch include: 1. Products with high certainty for overseas expansion certified by MNCs: PD-1 upgraded products from Sanofi and GLP-1 assets from Federal Pharmaceuticals [21]. 2. Potential blockbuster products for overseas licensing from MNCs: PD-1 upgraded products from Kangfang Biotech and Innovent Biologics, breakthroughs in autoimmune fields from Yifang Biotech and China Antibody, and innovative target ADCs from Fuhong Hanlin and Shiyao Group [21]. 3. Companies likely to benefit from medical insurance negotiations and innovative drug directories: Heng Rui Medicine, Kangnuo Pharmaceutical, Maiwei Biotech, Zhixiang Jintai, and Haichuang Pharmaceutical [21]. Summary by Sections Weekly New Drug Market Review - From October 13 to October 19, 2025, the top five gainers in the new drug sector were: - Sanofi National Health (+12.68%) - Kangning Jereh (+10.18%) - Rongchang Biotech (+5.42%) - Xiansheng Pharmaceuticals (+4.88%) - Qianyan Biotech (+3.77%) - The top five losers were: - Yongtai Biotech (-29.76%) - Betta Pharmaceuticals (-16.98%) - Yiming Oncology (-16.80%) - Deqi Pharmaceuticals (-15.30%) - WuXi Biologics (-13.43%) [4][16]. New Drug Industry Focus Analysis - Recently, Bai Li Tianheng presented overseas multi-center solid tumor research data for its EGFR×HER3 dual antibody ADC drug, iza-bren, at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The data showed consistent efficacy and safety across different populations, confirming the broad-spectrum tumor-killing efficacy of iza-bren [21][24]. New Drug Approval and Acceptance - This week, one new drug or new indication application was approved, and 13 new drug or new indication applications were accepted in China [9][27]. - Additionally, 30 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [10][30].

Core Insights - The recent surge in business development (BD) transactions in the pharmaceutical industry highlights a growing trend, with five deals involving companies like Hansoh Pharmaceutical and Roche, totaling over $4.2 billion [1][2][3] - Hansoh Pharmaceutical's collaboration with Roche involves a licensing agreement for the ADC drug HS-20110, which is currently in clinical trials for colorectal cancer and other solid tumors [1][11] - The partnership reflects Roche's strategic need to enhance its product pipeline in the competitive ADC market, where it faces increasing pressure from other pharmaceutical companies [5][6] Group 1: Business Development Transactions - Five BD transactions were disclosed recently, involving companies such as Hansoh Pharmaceutical, Roche, and others, with a total value exceeding $4.2 billion [1] - The deals primarily focus on high-barrier, unmet clinical needs, indicating a strategic shift towards innovative drug development [1][2] - Hansoh's licensing agreement with Roche includes an upfront payment of $80 million and potential milestone payments of up to $1.45 billion [1][11] Group 2: Market Dynamics and Competitive Landscape - Roche has been a leader in the ADC space but is facing increasing competition from other companies developing next-generation ADCs [5][6] - The ADC market is becoming crowded, with multiple companies targeting the CDH17 pathway, which is seen as a promising area for cancer treatment [12][13] - The demand for innovative treatments, particularly for colorectal cancer, is rising, with over 510,000 new cases reported annually in China alone [11][12] Group 3: Hansoh Pharmaceutical's Innovation Strength - Hansoh Pharmaceutical has successfully transitioned from generic to innovative drug development, with a robust pipeline of products targeting major diseases [7][9] - The company's revenue for the first half of the year reached approximately 7.43 billion RMB, with a year-on-year growth of about 14.3%, driven largely by innovative drug sales [10] - Notable products include the first original third-generation EGFR-TKI in China, which has been included in multiple national treatment guidelines [9][10]

Core Viewpoint - The stock price of Bohan Biotech (06955) has declined over 30% since reaching a peak of 19.90 HKD on August 8, 2023, and is now facing pressure to maintain its status in the Hong Kong Stock Connect due to a decrease in average market capitalization [1][2] Group 1: Stock Performance - Bohan Biotech's average market capitalization has fallen to 6.651 billion HKD, approaching the Hong Kong Stock Connect exit threshold of 5.745 billion HKD [1] - The stock has been in a downward trend characterized by "price drop and volume shrinkage" since August, with significant trading volume declines observed [2][3] - On October 14, the stock price reached a low of 11.22 HKD, but there are signs of stabilization in the following trading days [1][5] Group 2: Market Dynamics - The company has faced challenges due to the introduction of centralized procurement for biosimilars, which could impact its valuation and market position [1][6] - Bohan Biotech's strategy of developing biosimilars has been crucial for its commercial success, but the centralized procurement poses a risk to its business model [6][7] - The centralized procurement initiated on August 1, 2023, includes several key monoclonal antibodies, directly affecting Bohan Biotech's products [7][8] Group 3: Competitive Landscape - Bohan Biotech's core product, Bevacizumab (博优诺®), faces intense competition with 11 approved biosimilars in the market, leading to price pressures [8][9] - The company has partnered with AstraZeneca for the exclusive promotion of Bevacizumab, but its market share remains low compared to competitors [8] - The pricing strategy post-procurement will be critical, as Bohan Biotech's pricing is competitive but may still struggle against established players [9]

Core Insights - Asset management institutions have shown a decline in enthusiasm for researching listed companies in Q3, with a 24.8% decrease in the number of companies surveyed compared to the previous quarter [1] - In contrast, during Q2, there was a significant increase of 49.31% in the number of companies surveyed as the market experienced a period of stagnation [1] - The focus of asset management institutions remains on technology stocks, with a growing interest in pharmaceutical and medical stocks [2] Group 1: Research Activity - In the first three quarters, insurance asset management companies conducted 7,687 surveys on 5,850 individual stocks, with a majority focused on Shenzhen Main Board and Sci-Tech Innovation Board, accounting for 26.92% and 25.91% respectively [2] - The most active insurance asset management company, Taikang Asset, surveyed 860 companies, focusing primarily on the Shanghai Main Board [2] - Broker asset management companies surveyed 4,216 times, with 3,321 individual stocks, showing a preference for high-growth potential and technology-intensive companies [2][3] Group 2: Sector Preferences - In Q3, the Sci-Tech 50 index rose by 49.02%, significantly outperforming the Shanghai and Shenzhen 300 index, which increased by 17.9% [4] - Insurance asset management companies surveyed 600 companies on the Sci-Tech Innovation Board in Q3, making it the most surveyed sector, followed by the Shenzhen Main Board [4] - The most favored stocks among research institutions in Q3 included Mindray Medical, with 538 institutions conducting surveys, followed by Huichuan Technology and Maiwei Biomedical [5]